Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes for a period of up to 90 and 180 days. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Website: senseonics.com



Growth: Good revenue growth rate 33.3%, there is slowdown compared to average historical growth rates 69.0%. The revenue growth dynamics is moderately stable Site traffic for the last 3 months showed a change of -46.2%

Profitability: LTM EBITDA margin is positive, +304.5%. On average the margin is decreasing steadily. Gross margin is low, +13.6%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.10 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 12.6% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 26.6% higher than minimum and 87.8% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 19.3x by EV / Sales multiple , the company can be 56.6% undervalued

Key Financials (Download financials)

Ticker: SENS
Share price, USD:  (-2.5%)0.5049
year average price 0.6198  


year start price 0.6144 2023-05-07

max close price 1.0500 2023-07-18

min close price 0.3988 2024-04-22

current price 0.5049 2024-05-05
Common stocks: 567 974 492

Dividend Yield:  0.0%
FCF Yield LTM: 12.6%
EV / LTM EBITDA: 4.1x
EV / EBITDA annualized: 3.4x
Last revenue growth (y/y):  33.3%
Last growth of EBITDA (y/y):  -45.9%
Historical revenue growth:  69.0%
Historical growth of EBITDA:  30.7%
EV / Sales: 12.4x
Margin (EBITDA LTM / Revenue): 304.5%
Fundamental value created in LTM:
Market Cap ($m): 287
Net Debt ($m): -15
EV (Enterprise Value): 272
Price to Book: 3.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-05-02Business Wire

Senseonics Holdings, Inc. to Participate in Upcoming Conferences

2024-02-29Zacks Investment Research

Senseonics Holdings (SENS) Reports Q4 Loss, Tops Revenue Estimates

2023-11-09Seeking Alpha

Senseonics Holdings, Inc. (SENS) Q3 2023 Earnings Call Transcript

2023-08-10Zacks Investment Research

Senseonics Holdings (SENS) Reports Q2 Loss, Misses Revenue Estimates

2023-08-10Seeking Alpha

Senseonics Holdings, Inc. (SENS) Q2 2023 Earnings Call Transcript

2023-06-21PennyStocks

3 Penny Stocks to Buy For Under $4 But Are They Worth The Risk?

2023-06-02Market Watch

Senseonics shares jump 6.7% on new insurance coverage for continuous glucose monitor

2023-05-09Zacks Investment Research

Senseonics Holdings (SENS) Reports Q1 Loss, Tops Revenue Estimates

2023-05-09Seeking Alpha

Senseonics Holdings, Inc. (SENS) Q1 2023 Earnings Call Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol SENS SENS SENS SENS SENS SENS SENS
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-01 2023-11-09 2023-08-10 2023-05-09 2023-03-16 2022-11-08 2022-08-09
acceptedDate 2024-02-29 18:24:21 2023-11-09 16:27:15 2023-08-10 16:45:46 2023-05-09 16:16:10 2023-03-15 20:16:11 2022-11-08 16:13:15 2022-08-09 16:16:34
calendarYear 2023.000 2023.000 2022.000 2022.000 2022.000 2022.000 2022.000
period Q2 Q1 Q4 Q3 Q4 Q3 Q2
revenue 8M 6M 4M 4M 6M 5M 4M
costOfRevenue 7M 5M 4M 4M 5M 4M 3M
grossProfit 1M 1M 417 000 414 000 619 000 756 000 824 000
grossProfitRatio 0.136 0.192 0.101 0.100 0.111 0.164 0.222
researchAndDevelopmentExpenses 11M 13M 13M 12M 12M 11M 9M
generalAndAdministrativeExpenses 0 0 0 0 6M 0 0
sellingAndMarketingExpenses 0 0 0 0 -2M 0 0
sellingGeneralAndAdministrativeExpenses 7M 7M 7M 8M 8M 7M 9M
otherExpenses 8000.000 15 000 155 000 23 000 10000.000 0 -52 000
operatingExpenses 18M 20M 20M 20M 19M 18M 18M
costAndExpenses 25M 25M 24M 24M 24M 22M 21M
interestIncome 1M 1M 1M 1M 946 000 544 000 241 000
interestExpense 2M 2M 2M 5M 5M 5M 5M
depreciationAndAmortization 636 000 187 000 218 000 1M 956 000 734 000 257 000
ebitda -16M -18M -18M -19M -18M -17M 109M
ebitdaratio -2.038 -2.878 -4.407 -4.491 -3.214 -3.642 29.348
operatingIncome -17M -19M -20M -20M -19M -18M -17M
operatingIncomeRatio -2.118 -3.120 -4.815 -4.764 -3.386 -3.801 -4.587
totalOtherIncomeExpensesNet -186 000 -4M 444 000 21M 30M -43M 126M
incomeBeforeTax -17M -24M -20M 1M 12M -60M 104M
incomeBeforeTaxRatio -2.141 -3.953 -4.950 0.320 2.075 -13.066 28.064
incomeTaxExpense 1.000 2M 2M -16M 14M 43M 0
netIncome -17M -24M -20M 18M -2M -103M 104M
netIncomeRatio -2.141 -3.953 -4.950 4.280 -0.420 -22.331 28.064
eps -0.032 -0.041 -0.036 0.036 -0.005 -0.220 0.220
epsdiluted -0.032 -0.041 -0.036 0.033 -0.004 -0.220 0.170
weightedAverageShsOut 530M 592M 567M 497M 468M 472M 464M
weightedAverageShsOutDil 530M 592M 567M 541M 618M 472M 601M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol SENS SENS SENS SENS SENS SENS SENS
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-01 2023-11-09 2023-08-10 2023-05-09 2023-03-16 2022-11-08 2022-08-09
acceptedDate 2024-02-29 18:24:21 2023-11-09 16:27:15 2023-08-10 16:45:46 2023-05-09 16:16:10 2023-03-15 20:16:11 2022-11-08 16:13:15 2022-08-09 16:16:34
calendarYear 2023.000 2023.000 2022.000 2022.000 2022.000 2022.000 2022.000
period Q2 Q1 Q4 Q3 Q4 Q3 Q2
cashAndCashEquivalents 76M 56M 29M 45M 36M 35M 45M
shortTermInvestments 34M 70M 89M 83M 108M 119M 94M
cashAndShortTermInvestments 109M 125M 118M 128M 144M 154M 139M
netReceivables 5M 3M 6M 3M 2M 2M 220 000
inventory 9M 10M 9M 8M 7M 7M 7M
otherCurrentAssets 7M 8M 235 000 6M 7M 36 000 7M
totalCurrentAssets 130M 146M 138M 146M 161M 169M 158M
propertyPlantEquipmentNet 6M 934 000 925 000 1M 1M 1M 1M
goodwill 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0
longTermInvestments 0 0 7M 8M 12M 9M 11M
taxAssets 0 0 0 0 0 0 0
otherNonCurrentAssets 2M 7M 7M 3M 3M 3M 4M
totalNonCurrentAssets 8M 8M 15M 12M 16M 13M 17M
otherAssets 1.000 0 0 0 0 0 0
totalAssets 138M 154M 153M 159M 178M 183M 175M
accountPayables 5M 3M 975 000 646 000 419 000 684 000 2M
shortTermDebt 368 000 413 000 483 000 661 000 16M 44M 16M
taxPayables 0 0 0 0 0 0 0
deferredRevenue 0 -413 000 0 -661 000 0 0 0
otherCurrentLiabilities 12M 15M 14M 14M 15M 13M 14M
totalCurrentLiabilities 17M 17M 16M 14M 31M 58M 31M
longTermDebt 41M 47M 46M 40M 56M 56M 51M
deferredRevenueNonCurrent 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0
otherNonCurrentLiabilities 6M 38M 39M 40M 92M 95M 77M
totalNonCurrentLiabilities 48M 85M 85M 80M 149M 140M 128M
otherLiabilities 1.000 0 0 0 0 0 0
capitalLeaseObligations 6M 6M 7M 3M 3M 4M 705 000
totalLiabilities 65M 102M 101M 94M 180M 198M 159M
preferredStock 38M 38M 38M 38M 0 0 0
commonStock 530 000 528 000 493 000 480 000 480 000 478 000 465 000
retainedEarnings -869M -852M -828M -808M -809M -820M -760M
accumulatedOtherComprehensiveIncomeLoss -11 000 -59 000 -120 000 -220 000 -678 000 -1M -1M
othertotalStockholdersEquity 905M 866M 842M 834M 806M 806M 777M
totalStockholdersEquity 73M 52M 53M 64M -3M -15M 16M
totalEquity 73M 52M 53M 64M -3M -15M 16M
totalLiabilitiesAndStockholdersEquity 138M 154M 153M 159M 178M 183M 175M
minorityInterest 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 138M 154M 153M 159M 178M 183M 175M
totalInvestments 34M 70M 97M 92M 120M 128M 105M
totalDebt 48M 47M 46M 40M 72M 100M 66M
netDebt -28M -9M 17M -5M 36M 65M 21M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol SENS SENS SENS SENS SENS SENS SENS
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-01 2023-11-09 2023-08-10 2023-05-09 2023-03-16 2022-11-08 2022-08-09
acceptedDate 2024-02-29 18:24:21 2023-11-09 16:27:15 2023-08-10 16:45:46 2023-05-09 16:16:10 2023-03-15 20:16:11 2022-11-08 16:13:15 2022-08-09 16:16:34
calendarYear 2023.000 2023.000 2022.000 2022.000 2022.000 2022.000 2022.000
period Q2 Q1 Q4 Q3 Q4 Q3 Q2
netIncome -17M -24M -20M 1M 12M -60M 104M
depreciationAndAmortization 636 000 187 000 218 000 236 000 234 000 231 000 257 000
deferredIncomeTax -2M 2M -339 000 0 0 0 0
stockBasedCompensation 2M 2M 3M 2M 2M 2M 3M
changeInWorkingCapital -930 000 -625 000 -1M -1M -200 000 2M 1M
accountsReceivables -1M 226 000 -271 000 -953 000 -327 000 2M -14 000
inventory 865 000 -686 000 -949 000 -874 000 -48 000 -7000.000 -97 000
accountsPayables 2M 113 000 329 000 227 000 -266 000 -1M -356 000
otherWorkingCapital -2M -278 000 -275 000 355 000 441 000 835 000 0
otherNonCashItems 3M 3M 856 000 -22M -31M 42M 0
netCashProvidedByOperatingActivities -15M -17M -18M -20M -17M -15M -14M
investmentsInPropertyPlantAndEquipment -170 000 -123 000 0 -57 000 -57 000 -44 000 0
acquisitionsNet 0 123 000 0 0 -110M 0 0
purchasesOfInvestments 0 -7M -52M -10M -22M 0 0
salesMaturitiesOfInvestments 36M 34M 48M 40M 29M 60M 23M
otherInvestingActivites 36M -123 000 0 0 110M -83M -74 000
netCashUsedForInvestingActivites 36M 28M -4M 30M 7M -23M 22M
debtRepayment -24M -8M 0 -16M -3M 0 -732 000
commonStockIssued 2000.000 123 000 7M -65 000 34.174 0 0
commonStockRepurchased -1M 0 -2M 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0
otherFinancingActivites 23M 24M 0 15M 13M 27M -1M
netCashUsedProvidedByFinancingActivities -1M 17M 6M -807 000 10M 27M -2M
effectOfForexChangesOnCash 0 0 0 0 0 0 0
netChangeInCash 20M 27M -17M 9M 309 000 -10M 6M
cashAtEndOfPeriod 76M 56M 29M 45M 36M 35M 45M
cashAtBeginningOfPeriod 56M 29M 45M 36M 35M 45M 39M
operatingCashFlow -15M -17M -18M -20M -17M -15M -14M
capitalExpenditure -170 000 -123 000 0 -57 000 -57 000 -44 000 -74 000
freeCashFlow -15M -17M -18M -20M -17M -15M -14M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-29 ET (fiscal 2023 q4)
2023 q3
2023-11-09 ET (fiscal 2023 q3)
2023 q2
2023-08-10 ET (fiscal 2023 q2)
2023 q1
2023-05-09 ET (fiscal 2023 q1)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-09 ET (fiscal 2022 q2)
2022 q1
2022-05-10 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-02-29 21:05 ET
Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-15 21:05 ET
Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 29, 2024 at 4:30 P.M. Eastern Time
2024-02-12 12:00 ET
MEDICARE COVERAGE SIGNIFICANTLY EXPANDED FOR THE EVERSENSE E3 CGM SYSTEM
2024-02-12 12:00 ET
Medicare Coverage Significantly Expanded for the Eversense E3 CGM System
2024-02-06 13:00 ET
PHC Holdings Corporation and Senseonics Announce Appointment of Brian Hansen as President of CGM at Ascensia Diabetes Care
2024-01-02 21:05 ET
Senseonics Holdings, Inc. Announces Business Updates
2023-11-09 21:05 ET
Senseonics Holdings, Inc. Reports Third Quarter 2023 Financial Results
2023-11-09 13:05 ET
Senseonics Holdings, Inc. to Participate in the Stifel 2023 Healthcare Conference
2023-10-30 20:05 ET
Senseonics Holdings, Inc Schedules Third Quarter 2023 Earnings Release and Conference Call for November 9, 2023 at 4:30 p.m. Eastern Time
2023-10-09 11:00 ET
Ascensia Diabetes Care and Senseonics Announce 'The CGM for Real Life' Campaign to Raise Awareness of How Long-Term Eversense E3 Empowers People with Diabetes
2023-10-09 11:00 ET
Ascensia Diabetes Care and Senseonics Announce ‘The CGM for Real Life’ Campaign to Raise Awareness of How Long-Term Eversense E3 Empowers People with Diabetes
2023-09-26 12:05 ET
Senseonics Announces the Last Patient Completion of the 365-Day ENHANCE Pivotal Clinical Study
2023-09-14 12:05 ET
Senseonics Holdings, Inc. to Participate in the Gilmartin Group Emerging Growth Company Showcase
2023-09-11 12:05 ET
Senseonics Holdings, Inc. Enters Into $50 Million Loan Facility With Hercules Capital
2023-08-10 20:15 ET
Senseonics Holdings, Inc. Reports Second Quarter 2023 Financial Results
2023-07-27 20:05 ET
Senseonics Holdings, Inc. Schedules Second Quarter 2023 Earnings Release and Conference Call for August 10, 2023 at 4:30 p.m. Eastern Time
2023-07-05 20:05 ET
Senseonics Announces Equity Grants To Employees Under Inducement Plan
2023-06-26 11:30 ET
New Clinical Data Demonstrating the Safety and Accuracy of Eversense through 365 Days Presented at the American Diabetes Association 83rd Scientific Sessions
2023-06-02 11:00 ET
Senseonics Announces UnitedHealthcare Coverage of Eversense® E3 CGM for Adults with Diabetes
2023-05-26 11:00 ET
Senseonics to Participate in the Jefferies Healthcare Conference
2023-05-09 20:05 ET
Senseonics Holdings, Inc. Reports First Quarter 2023 Financial Results
2023-05-09 11:00 ET
ASCENSIA DIABETES CARE EXPANDS PAYMENT ASSISTANCE AND SIMPLE SAVINGS PROGRAM FOR EVERSENSE E3 CGM SYSTEM
2023-04-27 20:05 ET
Senseonics Holdings, Inc. Schedules First Quarter 2023 Earnings Release and Conference Call for May 9, 2023, at 4:30 p.m. Eastern Time
2023-04-24 11:00 ET
ASCENSIA DIABETES CARE MARKS ONE-YEAR ANNIVERSARY OF US EVERSENSE E3 CGM LAUNCH WITH COMMERCIAL UPDATE AND INNOVATION OUTLOOK
2023-04-18 20:15 ET
Senseonics Announces the First Pediatric Study Participant Insertions in the ENHANCE Clinical Trial
2023-04-05 12:00 ET
Senseonics Announces Equity Grants To Employees Under Inducement Plan
2023-03-15 20:05 ET
Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results
2023-02-17 13:00 ET
Senseonics Holdings, Inc. and PHC Holdings Corporation To Host Joint Eversense CGM Virtual Analyst and Investor Event on March 15, 2023
2023-01-05 22:58 ET
Senseonics Announces Equity Grants To Employees Under Inducement Plan
2022-11-09 21:05 ET
Senseonics to Present at the Stifel 2022 Healthcare Conference
2022-11-08 21:05 ET
Senseonics Holdings, Inc. Reports Third Quarter 2022 Financial Results
2022-11-07 06:00 ET
ASCENSIA DIABETES CARE ANNOUNCES GLOBAL INTEGRATION OF THE EVERSENSE CGM SYSTEM WITH APPLE HEALTH
2022-11-03 12:00 ET
Senseonics and Ascensia Announce a Collaboration with the Nurse Practitioner Group Designed to Expand Patient Access by Providing In-Office and At-Home Insertion Options for Eversense® E3 Continuous Glucose Monitoring System (CGM)
2022-11-03 12:00 ET
Senseonics and Ascensia Announce a Collaboration with the Nurse Practitioner Group Designed to Expand Patient Access by Providing In-Office and At-Home Insertion Options for Eversense® E3 Continuous Glucose Monitoring System (CGM)
2022-10-25 20:05 ET
Senseonics Holdings, Inc. Schedules Third Quarter 2022 Earnings Release and Conference Call for November 8, 2022, at 4:30 p.m. Eastern Time
2022-10-06 12:00 ET
Senseonics Announces Equity Grants To Employees Under Inducement Plan
2022-09-07 20:05 ET
Senseonics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
2022-09-01 20:10 ET
Senseonics Announces CFO Transition
2022-08-17 20:05 ET
Senseonics to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
2022-08-09 20:05 ET
Senseonics Holdings, Inc. Reports Second Quarter 2022 Financial Results
2022-08-03 11:00 ET
Senseonics Announces a Positive Coverage Decision for Eversense® E3 CGM from Anthem
2022-07-26 20:05 ET
Senseonics Holdings, Inc. Schedules Second Quarter 2022 Earnings Release and Conference Call for August 9, 2022, at 4:30 p.m. Eastern Time
2022-07-05 20:44 ET
Senseonics Announces Equity Grants To Employees Under Inducement Plan
2022-06-16 10:30 ET
Senseonics Announces CE Mark Approval of the Eversense E3 Continuous Glucose Monitoring System
2022-05-26 20:05 ET
Senseonics to Participate in the Jefferies Healthcare Conference
2022-05-16 20:05 ET
Senseonics to Participate in the H.C. Wainwright Global Investment Conference
2022-05-10 20:05 ET
Senseonics Holdings, Inc. Reports First Quarter 2022 Financial Results
2022-04-26 20:05 ET
Senseonics Holdings, Inc. Schedules First Quarter 2022 Earnings Release and Conference Call for May 10, 2022, at 4:30 p.m. Eastern Time
2022-04-06 20:34 ET
Senseonics Announces the First Patient Implant of the Eversense E3 CGM System in the U.S.
2022-04-01 23:45 ET
Senseonics Announces Equity Grants to Employees Under Inducement Plan
2022-03-01 21:05 ET
Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results
2022-02-15 21:05 ET
Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for March 1, 2022, at 4:30 p.m. Eastern Time
2022-02-14 12:00 ET
ASCENSIA DIABETES CARE ANNOUNCES FDA APPROVAL OF THE EVERSENSE E3 CONTINUOUS GLUCOSE MONITORING SYSTEM FOR USE FOR UP TO 6 MONTHS
2022-02-11 12:00 ET
Senseonics Announces FDA Approval of the Eversense® E3 Continuous Glucose Monitoring System for Use for Up to 6 months; Provides 2022 Business Outlook
2022-01-05 13:00 ET
Senseonics Announces Equity Grants To Employees Under Inducement Plan
2022-01-04 21:45 ET
Senseonics Announces Business Updates
2021-12-21 13:00 ET
Eversense NOW Remote Monitoring App for Android Users Receives CE Mark in Europe
2021-11-09 21:05 ET
Senseonics Holdings, Inc. Reports Third Quarter 2021 Financial Results
2021-11-08 21:05 ET
Senseonics to Participate in Upcoming November Investor Conferences
2021-10-26 20:05 ET
Senseonics Holdings, Inc. Schedules Third Quarter 2021 Earnings Release and Conference Call for November 9, 2021, at 4:30 p.m. Eastern Time
2021-10-04 20:05 ET
Senseonics Announces Equity Grants To Employees Under Inducement Plan
2021-09-13 20:05 ET
Senseonics Announces a Collaboration with the University Hospitals Accountable Care Organization (UHACO) in Cleveland, Ohio
2021-09-09 22:59 ET
Senseonics to Participate in the H.C. Wainwright Global Investment Conference
2021-08-09 20:05 ET
Senseonics Holdings, Inc. Reports Second Quarter 2021 Financial Results
2021-07-26 20:05 ET
Senseonics Holdings, Inc. Schedules Second Quarter 2021 Earnings Release and Conference Call for August 9, 2021, at 4:30 p.m. Eastern Time
2021-07-02 20:05 ET
Senseonics Announces Equity Grants To Employees Under Inducement Plan
2021-06-28 12:00 ET
Senseonics Announces Presentation of PROMISE Data at the American Diabetes Association 81st Scientific Sessions
2021-06-03 20:05 ET
Senseonics Announces Results of the PROMISE Study Demonstrating Strong Accuracy of 180 Day CGM Sensor
2021-05-13 20:05 ET
Senseonics Holdings, Inc. Reports First Quarter 2021 Financial Results
2021-04-29 20:05 ET
Senseonics Holdings, Inc. Schedules First Quarter 2021 Earnings Release and Conference Call for May 13, 2021 at 4:30 p.m. Eastern Time
2021-04-01 23:55 ET
Senseonics Announces Equity Grants To Employees Under Inducement Plan
2021-03-04 21:05 ET
Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results
2021-03-02 22:29 ET
Senseonics to Participate in the H.C. Wainwright Global Life Sciences Conference
2021-02-19 13:00 ET
Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2020 Earnings Release and Conference Call for March 4, 2021 at 4:30 p.m. Eastern Time
2021-02-11 21:05 ET
Senseonics to Participate in the SVB Leerink Global Healthcare Conference
2021-02-01 13:00 ET
Senseonics Announces Initiation of European Commercial Efforts by Partner Ascensia Diabetes Care
2021-01-29 04:33 ET
Senseonics Holdings Announces Closing of $115.0 Million Bought Deal Offering of Common Stock and Full Exercise of the Option to Purchase Additional Shares
2021-01-22 05:18 ET
Senseonics Holdings Increases Previously Announced Bought Deal Offering of Common Stock to $100.0 Million
2021-01-21 22:13 ET
Senseonics Holdings Announces $50.0 Million Bought Deal Offering of Common Stock
2021-01-19 13:00 ET
Senseonics Announces a Positive Coverage Decision for Eversense CGM from EmblemHealth
2021-01-18 03:22 ET
Senseonics Holdings Announces $50.0 Million Registered Direct Offering of Common Stock
2021-01-06 21:05 ET
Senseonics Announces Equity Grants To Employees Under Inducement Plan
2020-12-23 21:49 ET
Senseonics Announces Business Update
2020-11-09 21:05 ET
Senseonics Holdings, Inc. Reports Third Quarter 2020 Financial Results
2020-11-09 21:04 ET
Senseonics Announces Equity Line of Credit Financing Agreement
2020-11-05 21:05 ET
Senseonics to Participate in the Credit Suisse Healthcare Conference
2020-10-28 20:05 ET
Senseonics Holdings, Inc. Schedules Third Quarter 2020 Earnings Release and Conference Call for November 9, 2020 at 4:30 p.m. Eastern Time
2020-10-06 12:30 ET
Senseonics Announces Equity Grants To Employees Under Inducement Plan
2020-10-05 11:30 ET
Senseonics Submits PMA Application for 180-Day Eversense System to the FDA
2020-09-08 21:30 ET
Senseonics Announces Analyst and Investor Event on September 15, 2020
2020-09-01 12:00 ET
Local Coverage Determinations for Implantable CGMs Announced by Three Medicare Administrative Contractors
2020-08-10 20:07 ET
Senseonics Holdings, Inc. Reports Second Quarter 2020 Financial Results
2020-08-10 20:05 ET
Senseonics Announces Strategic Collaboration with Ascensia Diabetes Care
2020-08-07 12:00 ET
Senseonics Announces Positive Coverage Decision for Eversense CGM from Highmark Inc.
2020-08-03 20:05 ET
Senseonics Holdings, Inc. Schedules Second Quarter 2020 Earnings Release and Conference Call for August 10, 2020 at 4:30 p.m. Eastern Time
2020-07-02 20:05 ET
Senseonics Announces Equity Grants to Employees Under Inducement Plan
2020-06-09 20:05 ET
Senseonics Holdings, Inc. Reports First Quarter 2020 Financial Results
2020-05-28 20:37 ET
Senseonics Holdings, Inc. Schedules First Quarter 2020 Earnings Release and Conference Call for June 9, 2020 at 4:30 p.m. Eastern Time
2020-05-26 20:17 ET
Senseonics Launches New Remote Monitoring App for Android Users in US
2020-05-14 13:00 ET
 Local Coverage Determination Proposed for Implantable Continuous Glucose Monitors by Medicare Administrative Contractors
2020-05-06 20:05 ET
Senseonics Announces Positive Coverage Decision for Eversense CGM from Several Blue Cross Blue Shield Plans
2020-04-28 20:15 ET
Senseonics Eversense® Sensor Receives MRI Conditional Approval in Europe
2020-04-22 12:11 ET
Senseonics Enters into New Credit Facilities with Certain Funds Managed by Highbridge Capital Management, LLC
2020-04-03 20:15 ET
Senseonics Announces Equity Grants To Employees Under Inducement Plan
2020-03-23 12:26 ET
Senseonics Exploring Strategic Options to Enhance Stakeholder Value
2020-03-12 20:05 ET
Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results
2020-03-04 21:05 ET
Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2019 Earnings Release and Conference Call for March 12, 2020 at 4:30 p.m. Eastern Time
2020-02-26 13:30 ET
Senseonics Announces the FDA Approval to Continue the PROMISE Sensor Clinical Study in an Extended Cohort to 365 Days to Gather Feasibility Data
2020-02-24 13:00 ET
Senseonics Reports at ATTD Glycemic Outcomes Across Adult Age Ranges with Real-World Eversense CGM Use
2020-02-18 13:00 ET
Senseonics Announces a Positive Coverage Decision for Eversense CGM from Cigna
2020-02-11 13:00 ET
Senseonics Announces Partnership with Companion Medical
2020-01-03 21:05 ET
Senseonics Announces Equity Grants to Employees Under Inducement Plan
2019-12-02 21:05 ET
Senseonics Launches Eversense CGM System with Non-Adjunctive Claim in the U.S.
2019-11-21 22:22 ET
Senseonics Publishes Positive Longitudinal Performance Over Multiple Sensor Insertions and Removal Cycles of the Eversense® CGM System
2019-11-12 21:05 ET
Senseonics Holdings, Inc. Reports Third Quarter 2019 Financial Results
2019-11-12 21:03 ET
Medicare Establishes National Payment Rate for Eversense® CGM System

SEC forms

Show financial reports only

SEC form 10
2024-03-01 00:00 ET
Senseonics published news for 2023 q4
SEC form 10
2024-02-29 18:24 ET
Senseonics published news for 2023 q4
SEC form 8
2024-02-29 16:12 ET
Senseonics published news for 2023 q4
SEC form 8
2024-02-29 16:12 ET
Senseonics reported for 2023 q4
SEC form 10
2023-11-09 16:27 ET
Senseonics reported for 2023 q3
SEC form 8
2023-11-09 16:14 ET
Senseonics published news for 2023 q3
SEC form 10
2023-11-09 00:00 ET
Senseonics published news for 2023 q3
SEC form 10
2023-08-10 16:45 ET
Senseonics reported for 2023 q2
SEC form 6
2023-08-10 16:28 ET
Senseonics published news for 2023 q2
SEC form 8
2023-08-10 00:00 ET
Senseonics published news for 2023 q2
SEC form 10
2023-08-10 00:00 ET
Senseonics published news for 2023 q2
SEC form 10
2023-05-09 00:00 ET
Senseonics published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Senseonics published news for 2023 q1
SEC form 6
2023-04-06 16:05 ET
Senseonics published news for 2023 q1
SEC form 6
2023-04-03 17:28 ET
Senseonics published news for 2023 q1
SEC form 10
2023-03-16 00:00 ET
Senseonics reported for 2022 q4
SEC form 10
2023-03-15 20:16 ET
Senseonics reported for 2022 q4
SEC form 6
2023-03-15 16:24 ET
Senseonics published news for 2022 q4
SEC form 6
2023-03-15 16:21 ET
Senseonics published news for 2022 q4
SEC form 8
2023-03-15 00:00 ET
Senseonics reported for 2022 q4
SEC form 6
2023-01-10 16:44 ET
Senseonics published news for 2022 q4
SEC form 6
2022-11-14 16:09 ET
Senseonics published news for 2022 q3
SEC form 10
2022-11-08 16:13 ET
Senseonics reported for 2022 q3
SEC form 6
2022-11-08 16:10 ET
Senseonics published news for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Senseonics reported for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Senseonics reported for 2022 q3
SEC form 6
2022-09-01 17:19 ET
Senseonics published news for 2022 q2
SEC form 10
2022-08-09 16:16 ET
Senseonics reported for 2022 q2
SEC form 6
2022-08-09 16:14 ET
Senseonics published news for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Senseonics reported for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Senseonics reported for 2022 q2
SEC form 6
2022-05-26 16:05 ET
Senseonics published news for 2022 q1
SEC form 6
2022-05-10 16:40 ET
Senseonics published news for 2022 q1
SEC form 10
2022-05-10 16:28 ET
Senseonics reported for 2022 q1
SEC form 8
2022-05-10 00:00 ET
Senseonics reported for 2022 q1
SEC form 10
2022-05-10 00:00 ET
Senseonics reported for 2022 q1
SEC form 6
2022-04-15 16:46 ET
Senseonics published news for 2022 q1
SEC form 6
2022-03-15 17:23 ET
Senseonics published news for 2021 q4
SEC form 6
2022-03-01 16:39 ET
Senseonics published news for 2021 q4
SEC form 10
2022-03-01 16:29 ET
Senseonics published news for 2021 q4
SEC form 8
2022-03-01 00:00 ET
Senseonics published news for 2021 q4
SEC form 10
2022-03-01 00:00 ET
Senseonics published news for 2021 q4
SEC form 6
2022-02-11 07:18 ET
Senseonics published news for 2021 q4
SEC form 8
2022-02-11 00:00 ET
Senseonics published news for 2021 q4
SEC form 6
2021-12-09 16:40 ET
Senseonics published news for 2021 q3
SEC form 6
2021-11-09 17:27 ET
Senseonics published news for 2021 q3
SEC form 10
2021-11-09 16:05 ET
Senseonics published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
Senseonics published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
Senseonics published news for 2021 q3
SEC form 6
2021-09-13 08:38 ET
Senseonics published news for 2021 q2
SEC form 6
2021-08-11 17:20 ET
Senseonics published news for 2021 q2
SEC form 8
2021-08-11 00:00 ET
Senseonics published news for 2021 q2
SEC form 10
2021-08-09 16:38 ET
Senseonics published news for 2021 q2
SEC form 10
2021-08-09 00:00 ET
Senseonics published news for 2021 q2
SEC form 6
2021-06-01 17:27 ET
Senseonics published news for 2021 q1
SEC form 6
2021-05-13 16:19 ET
Senseonics published news for 2021 q1
SEC form 10
2021-05-13 16:05 ET
Senseonics published news for 2021 q1
SEC form 8
2021-05-13 00:00 ET
Senseonics published news for 2021 q1
SEC form 10
2021-05-13 00:00 ET
Senseonics published news for 2021 q1
SEC form 6
2021-04-21 21:05 ET
Senseonics published news for 2021 q1
SEC form 6
2021-04-13 16:09 ET
Senseonics published news for 2021 q1
SEC form 6
2021-03-08 07:11 ET
Senseonics published news for 2020 q4
SEC form 10
2021-03-05 16:07 ET
Senseonics published news for 2020 q4
SEC form 6
2021-01-26 16:22 ET
Senseonics published news for 2020 q4
SEC form 6
2021-01-21 16:01 ET
Senseonics published news for 2020 q4
SEC form 6
2021-01-19 08:55 ET
Senseonics published news for 2020 q4
SEC form 6
2021-01-12 08:00 ET
Senseonics published news for 2020 q4
SEC form 6
2020-11-12 07:47 ET
Senseonics published news for 2020 q3
SEC form 6
2020-11-09 16:54 ET
Senseonics published news for 2020 q3
SEC form 10
2020-11-09 16:29 ET
Senseonics published news for 2020 q3
SEC form 6
2020-10-26 16:23 ET
Senseonics published news for 2020 q3
SEC form 6
2020-10-06 16:15 ET
Senseonics published news for 2020 q3
SEC form 6
2020-09-04 16:15 ET
Senseonics published news for 2020 q2
SEC form 6
2020-08-19 16:07 ET
Senseonics published news for 2020 q2